Atorvastatin synergizes with IFN-γ in treating human non-small cell lung carcinomas via potent inhibition of RhoA activity

European Journal of Pharmacology

Volumn 682, Issue 1-3, 2012, Pages 161-170

  Chen, Jie ^a   Hou, Jincai ^b   Zhang, Jingjie ^a   An, Yu ^a   Zhang, Xiaojie ^b   Yue, Liling ^b   Liu, Jicheng ^b   Li, Xuejun ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b Medicine and Drug Research Institute   (China)

Author keywords

Atorvastatin; IFN ; Non small cell lung carcinomas; NSCLCs; RhoA

Indexed keywords

ATORVASTATIN; CYCLIN D1; GAMMA INTERFERON; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MYC PROTEIN; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; TRANSPORTER ASSOCIATED WITH ANTIGEN PROCESSING 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CARCINOMA CELL; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG MEGADOSE; DRUG POTENTIATION; FEMALE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TUMOR IMMUNITY; TUMOR XENOGRAFT; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SYNERGISM; ENZYME INHIBITORS; FEMALE; HEPTANOIC ACIDS; HUMANS; INTERFERON-GAMMA; LUNG NEOPLASMS; MICE; ORGAN SPECIFICITY; PYRROLES; RHOA GTP-BINDING PROTEIN;

EID: 84862809710     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2012.02.015     Document Type: Article

References (39)

1. S. Aznar, and J.C. Lacal Rho signals to cell growth and apoptosis Cancer Lett. 165 2001 1 10
2. C. Baigent, A. Keech, P.M. Kearney, L. Blackwell, G. Buck, C. Pollicino, A. Kirby, T. Sourjina, R. Peto, R. Collins, and R. Simes Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins Lancet 366 2005 1267 1278
3. A. Boni, A.P. Cogdill, P. Dang, D. Udayakumar, C.N. Njauw, C.M. Sloss, C.R. Ferrone, K.T. Flaherty, D.P. Lawrence, D.E. Fisher, H. Tsao, and J.A. Wargo Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function Cancer Res. 70 2010 5213 5219
4. Y.E. Chin, M. Kitagawa, W.C. Su, Z.H. You, Y. Iwamoto, and X.Y. Fu Cell growth arrest and induction of cyclin-dependent kinase inhibitor p21 WAF1/CIP1 mediated by STAT1 Science 272 1996 719 722
5. W.R. Coward, A. Marei, A. Yang, M.M. Vasa-Nicotera, and S.C. Chow Statin-induced proinflammatory response in mitogen-activated peripheral blood mononuclear cells through the activation of caspase-1 and IL-18 secretion in monocytes J. Immunol. 176 2006 5284 5292
6. C. Denoyelle, P. Albanese, G. Uzan, L. Hong, J.P. Vannier, J. Soria, and C. Soria Molecular mechanism of the anti-cancer activity of cerivastatin, an inhibitor of HMG-CoA reductase, on aggressive human breast cancer cells Cell. Signal. 15 2003 327 338
7. S. Ferrone, and F.M. Marincola Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance Immunol. Today 16 1995 487 494
8. G. Fritz, I. Just, and B. Kaina Rho GTPases are over-expressed in human tumors Int. J. Cancer 81 1999 682 687
9. O. Fromigue, Z. Hamidouche, and P.J. Marie Blockade of the RhoA-JNK-c-Jun-MMP2 cascade by atorvastatin reduces osteosarcoma cell invasion J. Biol. Chem. 283 2008 30549 30556
10. A. Garcia-Lora, I. Algarra, and F. Garrido MHC class I antigens, immune surveillance, and tumor immune escape J. Cell. Physiol. 195 2003 346 355
11. S. Ghavami, M.M. Mutawe, P. Sharma, B. Yeganeh, K.D. McNeill, T. Klonisch, H. Unruh, H.H. Kashani, D. Schaafsma, M. Los, and A.J. Halayko Mevalonate cascade regulation of airway mesenchymal cell autophagy and apoptosis: a dual role for p53 PLoS One 6 2011 e16523
12. M.E. Gleave, M. Elhilali, Y. Fradet, I. Davis, P. Venner, F. Saad, L.H. Klotz, M.J. Moore, V. Paton, and A. Bajamonde Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. Canadian Urologic Oncology Group N. Engl. J. Med. 338 1998 1265 1271
13. J.A. Gollob, C.J. Sciambi, Z. Huang, and H.K. Dressman Gene expression changes and signaling events associated with the direct antimelanoma effect of IFN-gamma Cancer Res. 65 2005 8869 8877
14. F.A. Greco, and J.D. Hainsworth Tumors of unknown origin CA Cancer J. Clin. 42 1992 96 115
15. G. Gruenbacher, H. Gander, O. Nussbaumer, W. Nussbaumer, A. Rahm, and M. Thurnher IL-2 costimulation enables statin-mediated activation of human NK cells, preferentially through a mechanism involving CD56 + dendritic cells Cancer Res. 70 2010 9611 9620
16. A. Hambrock, C.B. de Oliveira Franz, S. Hiller, and H. Osswald Glibenclamide-induced apoptosis is specifically enhanced by expression of the sulfonylurea receptor isoform SUR1 but not by expression of SUR2B or the mutant SUR1(M1289T) J. Pharmacol. Exp. Ther. 316 2006 1031 1037
17. B. Hildenbrand, B. Sauer, O. Kalis, C. Stoll, M.A. Freudenberg, G. Niedermann, J.M. Giesler, E. Juttner, J.H. Peters, B. Haring, R. Leo, C. Unger, and M. Azemar Immunotherapy of patients with hormone-refractory prostate carcinoma pre-treated with interferon-gamma and vaccinated with autologous PSA-peptide loaded dendritic cells-a pilot study Prostate 67 2007 500 508
18. A.C. Hobeika, W. Etienne, B.A. Torres, H.M. Johnson, and P.S. Subramaniam IFN-gamma induction of p21(WAF1) is required for cell cycle inhibition and suppression of apoptosis J. Interferon Cytokine Res. 19 1999 1351 1361
19. A. Hoque, H. Chen, and X.C. Xu Statin induces apoptosis and cell growth arrest in prostate cancer cells Cancer Epidemiol. Biomarkers Prev. 17 2008 88 94
20. M. Jakobisiak, and J. Golab Potential antitumor effects of statins (review) Int. J. Oncol. 23 2003 1055 1069
21. A.K. Johnsen, D.J. Templeton, M. Sy, and C.V. Harding Deficiency of transporter for antigen presentation (TAP) in tumor cells allows evasion of immune surveillance and increases tumorigenesis J. Immunol. 163 1999 4224 4231
22. T.T. Junttila, R.W. Akita, K. Parsons, C. Fields, G.D. Lewis Phillips, L.S. Friedman, D. Sampath, and M.X. Sliwkowski Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941 Cancer Cell 15 2009 429 440
23. W.H. Kim, C.Y. Chon, Y.M. Moon, J.K. Kang, I.S. Park, and H.J. Choi Effect of anticancer drugs and desferrioxamine in combination with radiation on hepatoma cell lines Yonsei Med. J. 34 1993 45 56
24. J.M. Kirkwood, M.S. Ernstoff, T. Trautman, G. Hebert, Y. Nishida, C.A. Davis, J. Balzer, S. Reich, J. Schindler, and S.A. Rudnick In vivo biological response to recombinant interferon-gamma during a phase I dose-response trial in patients with metastatic melanoma J. Clin. Oncol. 8 1990 1070 1082
25. L. Klampfer, J. Huang, G. Corner, J. Mariadason, D. Arango, T. Sasazuki, S. Shirasawa, and L. Augenlicht Oncogenic Ki-ras inhibits the expression of interferon-responsive genes through inhibition of STAT1 and STAT2 expression J. Biol. Chem. 278 2003 46278 46287
26. S. Kotamraju, C.L. Williams, and B. Kalyanaraman Statin-induced breast cancer cell death: role of inducible nitric oxide and arginase-dependent pathways Cancer Res. 67 2007 7386 7394
27. K. Mattson, A. Niiranen, S. Pyrhonen, M. Farkkila, and K. Cantell Recombinant interferon gamma treatment in non-small cell lung cancer. Antitumour effect and cardiotoxicity Acta Oncol. 30 1991 607 610
28. E. Pujade-Lauraine, J.P. Guastalla, N. Colombo, P. Devillier, E. Francois, P. Fumoleau, A. Monnier, M. Nooy, L. Mignot, R. Bugat, C. Marques, M. Mousseau, G. Netter, F. Maloisel, S. Larbaoui, and M. Brandely Intraperitoneal recombinant interferon gamma in ovarian cancer patients with residual disease at second-look laparotomy J. Clin. Oncol. 14 1996 343 350
29. C.V. Ramana, N. Grammatikakis, M. Chernov, H. Nguyen, K.C. Goh, B.R. Williams, and G.R. Stark Regulation of c-myc expression by IFN-gamma through Stat1-dependent and -independent pathways EMBO J. 19 2000 263 272
30. J.H. Schiller, B. Storer, J.K. Willson, and E.C. Borden Phase I trial of combinations of recombinant interferons beta(ser) and gamma in patients with advanced malignancy Cancer Treat. Rep. 71 1987 945 952
31. B. Seliger, A. Hohne, A. Knuth, H. Bernhard, T. Meyer, R. Tampe, F. Momburg, and C. Huber Analysis of the major histocompatibility complex class I antigen presentation machinery in normal and malignant renal cells: evidence for deficiencies associated with transformation and progression Cancer Res. 56 1996 1756 1760
32. B. Seliger, M.J. Maeurer, and S. Ferrone TAP off-tumors on Immunol. Today 18 1997 292 299
33. S. Sharma, L. Zhu, S.C. Yang, L. Zhang, J. Lin, S. Hillinger, B. Gardner, K. Reckamp, R.M. Strieter, M. Huang, R.K. Batra, and S.M. Dubinett Cyclooxygenase 2 inhibition promotes IFN-gamma-dependent enhancement of antitumor responses J. Immunol. 175 2005 813 819
34. P. Sterpetti, A.A. Hack, M.P. Bashar, B. Park, S.D. Cheng, J.H. Knoll, T. Urano, L.A. Feig, and D. Toksoz Activation of the Lbc Rho exchange factor proto-oncogene by truncation of an extended C terminus that regulates transformation and targeting Mol. Cell. Biol. 19 1999 1334 1345
35. A.F. Tilkin-Mariame, C. Cormary, N. Ferro, G. Sarrabayrouse, I. Lajoie-Mazenc, J.C. Faye, and G. Favre Geranylgeranyl transferase inhibition stimulates anti-melanoma immune response through MHC Class I and costimulatory molecule expression FASEB J. 19 2005 1513 1515
36. J.S. Weber, and S.A. Rosenberg Modulation of murine tumor major histocompatibility antigens by cytokines in vivo and in vitro Cancer Res. 48 1988 5818 5824
37. K.J. Whitehead, A.C. Chan, S. Navankasattusas, W. Koh, N.R. London, J. Ling, A.H. Mayo, S.G. Drakos, C.A. Jones, W. Zhu, D.A. Marchuk, G.E. Davis, and D.Y. Li The cerebral cavernous malformation signaling pathway promotes vascular integrity via Rho GTPases Nat. Med. 15 2009 177 184
38. J.M. Wroblewski, D.L. Bixby, C. Borowski, and J.R. Yannelli Characterization of human non-small cell lung cancer (NSCLC) cell lines for expression of MHC, co-stimulatory molecules and tumor-associated antigens Lung Cancer 33 2001 181 194
39. H. Zhou, W. Liu, Y. Su, Z. Wei, J. Liu, S.K. Kolluri, H. Wu, Y. Cao, J. Chen, Y. Wu, T. Yan, X. Cao, W. Gao, A. Molotkov, F. Jiang, W.G. Li, B. Lin, H.P. Zhang, J. Yu, S.P. Luo, J.Z. Zeng, G. Duester, P.Q. Huang, and X.K. Zhang NSAID sulindac and its analog bind RXRalpha and inhibit RXRalpha-dependent AKT signaling Cancer Cell 17 2010 560 573